Paper28474232
ETS-targeted therapy: can it substitute for MEK inhibitors?
Tetsu O and 1 other. Clin Transl Med, 2017. Cited by 37 papers, by iCite.
Cite this record
ConductScience Library. ETS-targeted therapy: can it substitute for MEK inhibitors? Papers, record 28474232. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28474232
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| R35 CA197709 | NCI NIH HHS | United States | R35CA197709 | PubMed |
Source NIH RePORTER
References108
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 1614856 | Serum, AP-1 and Ets-1 stimulate the human ets-1 promoter. | Nucleic Acids Res | 1992 | https://conductscience.org/library/papers/1614856 | PubMed |
| 2 | 11779502 | Structural studies of Ets-1/Pax5 complex formation on DNA. | Mol Cell | 2001 | https://conductscience.org/library/papers/11779502 | PubMed |
| 3 | 25399551 | Improved overall survival in melanoma with combined dabrafenib and trametinib. | N Engl J Med | 2015 | https://conductscience.org/library/papers/25399551 | PubMed |
| 4 | 19411629 | Ets1 and Ets2 are required for endothelial cell survival during embryonic angiogenesis. | Blood | 2009 | https://conductscience.org/library/papers/19411629 | PubMed |
| 5 | 8945521 | The transcriptional coactivators p300 and CBP are histone acetyltransferases. | Cell | 1996 | https://conductscience.org/library/papers/8945521 | PubMed |
| 6 | 8052857 | Transformation of mammalian cells by constitutively active MAP kinase kinase. | Science | 1994 | https://conductscience.org/library/papers/8052857 | PubMed |
| 7 | 28198367 | Usp9x regulates Ets-1 ubiquitination and stability to control NRAS expression and tumorigenicity in melanoma. | Nat Commun | 2017 | https://conductscience.org/library/papers/28198367 | PubMed |
| 8 | 2831462 | A Harvey-ras responsive transcription element is also responsive to a tumour-promoter and to serum. | Nature | 1988 | https://conductscience.org/library/papers/2831462 | PubMed |
| 9 | 20534573 | Ras signaling requires dynamic properties of Ets1 for phosphorylation-enhanced binding to coactivator CBP. | Proc Natl Acad Sci U S A | 2010 | https://conductscience.org/library/papers/20534573 | PubMed |
| 10 | 26453958 | AKT inactivation causes persistent drug tolerance to EGFR inhibitors. | Pharmacol Res | 2015 | https://conductscience.org/library/papers/26453958 | PubMed |
| 11 | 15572696 | Ras/mitogen-activated protein kinase signaling activates Ets-1 and Ets-2 by CBP/p300 recruitment. | Mol Cell Biol | 2004 | https://conductscience.org/library/papers/15572696 | PubMed |
| 12 | 16533420 | The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer. | Neoplasia | 2006 | https://conductscience.org/library/papers/16533420 | PubMed |
| 13 | 24751816 | Targeting bromodomains: epigenetic readers of lysine acetylation. | Nat Rev Drug Discov | 2014 | https://conductscience.org/library/papers/24751816 | PubMed |
| 14 | 22761467 | First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. | Clin Cancer Res | 2012 | https://conductscience.org/library/papers/22761467 | PubMed |
| 15 | 24450640 | Recent advances in the structural molecular biology of Ets transcription factors: interactions, interfaces and inhibition. | Biochem Soc Trans | 2014 | https://conductscience.org/library/papers/24450640 | PubMed |
| 16 | 25117710 | Phosphorylation of ETS1 by Src family kinases prevents its recognition by the COP1 tumor suppressor. | Cancer Cell | 2014 | https://conductscience.org/library/papers/25117710 | PubMed |
| 17 | 26333361 | Kinase-independent role for CRAF-driving tumour radioresistance via CHK2. | Nat Commun | 2015 | https://conductscience.org/library/papers/26333361 | PubMed |
| 18 | 17721441 | New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. | EMBO Rep | 2007 | https://conductscience.org/library/papers/17721441 | PubMed |
| 19 | 25885538 | Comparison of MAPK specificity across the ETS transcription factor family identifies a high-affinity ERK interaction required for ERG function in prostate cells. | Cell Commun Signal | 2015 | https://conductscience.org/library/papers/25885538 | PubMed |
| 20 | 1547944 | Molecular cloning and characterization of PEA3, a new member of the Ets oncogene family that is differentially expressed in mouse embryonic cells. | Genes Dev | 1992 | https://conductscience.org/library/papers/1547944 | PubMed |
Cited by27
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 37 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41876551 | Hh and EGFR-Ras signaling promote distinct steps of tumor progression in the Drosophila follicle epithelium. | Nat Commun | 2026 | https://conductscience.org/library/papers/41876551 | PubMed |
| 41425714 | ETS Family Transcription Factors in Gastric Cancer and the Role of ELF3 in the Core Metaplasia Transcription Factor Network. | Oncol Res | 2025 | https://conductscience.org/library/papers/41425714 | PubMed |
| 41145444 | Enhanced ETS1 stability by DNAPKcs orchestrates transcriptional changes during chemoresistance in triple negative breast cancer. | NPJ Breast Cancer | 2025 | https://conductscience.org/library/papers/41145444 | PubMed |
| 40214124 | Identification of novel small molecule inhibitors of ETS transcription factors. | FEBS Lett | 2025 | https://conductscience.org/library/papers/40214124 | PubMed |
| 40204967 | Transcriptional regulation of ETV5 by mitogen-activated protein kinase via ETS-1 in human pancreatic cancer cells. | Sci Rep | 2025 | https://conductscience.org/library/papers/40204967 | PubMed |
| 40177537 | Exploring recent advances in signaling pathways and hallmarks of uveal melanoma: a comprehensive review. | Explor Target Antitumor Ther | 2025 | https://conductscience.org/library/papers/40177537 | PubMed |
| 40149711 | Aberrant Expression and Oncogenic Activity of SPP1 in Hodgkin Lymphoma. | Biomedicines | 2025 | https://conductscience.org/library/papers/40149711 | PubMed |
| 39895280 | PROTACs coupled with oligonucleotides to tackle the undruggable. | Bioanalysis | 2025 | https://conductscience.org/library/papers/39895280 | PubMed |
| 39505854 | Fine-mapping and molecular characterisation of primary sclerosing cholangitis genetic risk loci. | Nat Commun | 2024 | https://conductscience.org/library/papers/39505854 | PubMed |
| 37254537 | ERK/MAPK Signalling Pathway Regulates MMP2 through ETS1 in Renal Clear Cell Carcinoma. | Curr Mol Med | 2024 | https://conductscience.org/library/papers/37254537 | PubMed |
| 36504910 | ETS1 is a prognostic biomarker of triple-negative breast cancer and promotes the triple-negative breast cancer progression through the YAP signaling. | Am J Cancer Res | 2022 | https://conductscience.org/library/papers/36504910 | PubMed |
| 36112236 | The rs1001179 SNP and CpG methylation regulate catalase expression in chronic lymphocytic leukemia. | Cell Mol Life Sci | 2022 | https://conductscience.org/library/papers/36112236 | PubMed |
| 35789155 | Ets1 mediates sorafenib resistance by regulating mitochondrial ROS pathway in hepatocellular carcinoma. | Cell Death Dis | 2022 | https://conductscience.org/library/papers/35789155 | PubMed |
| 35141153 | Identification of a Hypoxia-Related Gene Model for Predicting the Prognosis and Formulating the Treatment Strategies in Kidney Renal Clear Cell Carcinoma. | Front Oncol | 2021 | https://conductscience.org/library/papers/35141153 | PubMed |
| 34278178 | Dual-Specificity Phosphatase 9 Regulates Cellular Proliferation and Predicts Recurrence After Surgery in Hepatocellular Carcinoma. | Hepatol Commun | 2021 | https://conductscience.org/library/papers/34278178 | PubMed |
| 33869193 | Dynamics of m6A RNA Methylome on the Hallmarks of Hepatocellular Carcinoma. | Front Cell Dev Biol | 2021 | https://conductscience.org/library/papers/33869193 | PubMed |
| 33143299 | p53 Loss Mediates Hypersensitivity to ETS Transcription Factor Inhibition Based on PARylation-Mediated Cell Death Induction. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/33143299 | PubMed |
| 32552404 | Somatic Gain of KRAS Function in the Endothelium Is Sufficient to Cause Vascular Malformations That Require MEK but Not PI3K Signaling. | Circ Res | 2020 | https://conductscience.org/library/papers/32552404 | PubMed |
| 32477936 | ETS1 Suppresses Tumorigenesis of Human Breast Cancer via Trans-Activation of Canonical Tumor Suppressor Genes. | Front Oncol | 2020 | https://conductscience.org/library/papers/32477936 | PubMed |
| 31655920 | Molecular determinants of drug response in TNBC cell lines. | Breast Cancer Res Treat | 2020 | https://conductscience.org/library/papers/31655920 | PubMed |
Genes58
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28474232
GET https://conductscience.org/api/papers/v1/28474232/references?page=2